All AbMole products are for research use only, cannot be used for human consumption.
RAF265 (CHIR-265) is a novel, orally bioavailable dual inhibitor of RAF kinase and VEGFR2. RAF265 significantly enhanced TRAIL sensitivity in NCI-H727 and CM insulinoma cells by blocking Raf-MEK-Erk signalling. RAF265 strongly decreased Bcl-2 levels in those cell lines susceptible to its TRAIL-sensitizing action. RAF265 impaired in vitro differentiation of PBMCs to OCs induced by receptor activator of NF-kB ligand (RANKL) and M-CSF (IC(50) ≈ 160 nM). In parallel, RAF265 exerted a potent inhibition of OC resorptive capacity (IC(50) ≈ 20 nM). Moreover, RAF265 exhibits reduced pMEK1, reduced proliferation based upon reduced Ki-67, cyclin D1 and polo-like kinase1 levels, and induction of the apoptosis mediator BCL2-like 11. Using Raf-MEK-Erk pathway inhibitors and TRAIL together might offer a novel therapeutic strategy in NET disease.
 |
Source | Mol Cancer (2015). Figure 1.RAF265 |
| Method | MTT assay | |
| Cell Lines | HT29 and HCT116 cells | |
| Concentrations | 0–50 μM | |
| Incubation Time | 48 h | |
| Results | When treated with 1 μM Raf265 for 3 weeks, the number of colony formed reduced from 38.6 ± 6.5 and 28.3 ± 3.5 to 1.67 ± 1.15 and 0.67 ± 0.58 colonies for HT29 and HCT116 cells, respectively. |
| Cell Experiment | |
|---|---|
| Cell lines | HCT116, HT29, and MDAMB231 cell lines |
| Preparation method | Cell Viability Assay The MTT assay and Bliss additivism model were used to assess the effect of the combination on cell viability. In each well of a 96-well plate, 1 × 104 cells were grown in 200 μL of medium. After 24 h, RAD001, RAF265, or the combination was added to achieve a final concentration of 0.1 to 10 nmol/L and 0.1 to 10 μmol/L, respectively. After 48 h of treatment, 20 μL of 5 mg mL−1 MTT (Organics Research, Inc.) solution in PBS was added to each well. After 4 h, supernatant was removed and formazan crystals were discarded in 200 μL of DMSO. Absorbance was then measured at 595 nm using an absorbance plate reader (Bio-Rad Microplate Reader). Data are expressed as the percentage of viable cells in treated relative to nontreated conditions. |
| Concentrations | 0.1 to 10 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | mice bearing HCT116, A549 or MDAMB231 xenografts |
| Formulation | DMSO/PBS |
| Dosages | 12 mg/kg daily over 14 d (6 d on, 2 d off, 6 d on) |
| Administration | orally |
| Molecular Weight | 518.41 |
| Formula | C24H16F6N6O |
| CAS Number | 927880-90-8 |
| Solubility (25°C) | DMSO ≥90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Su et al. Clin Cancer Res. RAF265 inhibits the growth of advanced human melanoma tumors.
| Related Raf Products |
|---|
| Sorafenib-d3
Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. |
| XL-281
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. |
| B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor. |
| Brimarafenibum
Brimarafenibum (Brimarafenib) is a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor, wtih antineoplastic effect. |
| Belvarafenib TFA
Belvarafenib TFA (HM95573 TFA) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
